Related by context. All words. (Click for frequent words.) 74 locoregional recurrence 73 NMIBC 73 EBRT 72 external beam radiotherapy 72 intravesical therapy 72 Radical prostatectomy 72 TURBT 71 tumor necrosis 71 concurrent chemoradiation 71 adjuvant radiotherapy 71 debulking surgery 70 locoregional 70 postoperative chemotherapy 70 transplantation HCT 70 PSA nadir 70 radiochemotherapy 70 chemoradiation therapy 70 interferon ribavirin 70 prostate carcinoma 70 Platinol ® cisplatin 70 preoperative chemotherapy 69 pT3 69 5FU 69 relapsed MM 69 liver resection 69 biochemical recurrence 69 hepatic metastases 69 transabdominal 69 nicardipine 69 cytoreduction 69 colorectal liver metastases 69 5-fluorouracil/leucovorin 69 epirubicin cyclophosphamide 69 unresectable tumors 69 elevated transaminases 69 completely resected 69 transurethral 68 chemoradiotherapy 68 demonstrated antitumor activity 68 radioiodine therapy 68 postoperative morbidity 68 surgical debulking 68 papillary thyroid carcinoma 68 mucinous 68 aortic root replacement 68 CIMZIA ™ 68 neurologic progression 68 haematologic 68 intra arterial chemotherapy 68 liver metastasis 68 biochemical relapse 68 papillary renal cell carcinoma 68 FOLFOX6 68 Flu Cy 68 urothelial carcinoma 68 PEG IFN 68 gadolinium enhanced 68 Capecitabine 68 neoadjuvant chemotherapy 68 serum PTH 68 cystoscopic 68 dacarbazine DTIC 68 adriamycin 68 tumor resection 68 bronchoalveolar lavage 68 chemoembolization 68 adjuvant radiation 68 CTEPH 68 Mitomycin C 68 radical prostatectomy RP 68 ABVD 68 underwent resection 68 cisplatin gemcitabine 68 #F FDG 67 postoperative complication 67 esophagogastric 67 thymectomy 67 ritonavir boosted 67 adjuvant cisplatin 67 Toxicities 67 gemcitabine Gemzar 67 bioavailable testosterone 67 lenalidomide dexamethasone 67 neoadjuvant 67 FDG uptake 67 surgically resectable 67 intact parathyroid hormone 67 postoperative radiotherapy 67 total thyroidectomy 67 artery stenosis 67 clinically localized prostate 67 adrenalectomy 67 F FDG PET 67 fallopian tube carcinoma 67 pamidronate 67 cytoreductive surgery 67 Pharmacokinetics PK 67 Pegylated Interferon 67 histologic subtype 67 micafungin 67 erlotinib Tarceva ® 67 LV dysfunction 67 perioperatively 67 oral levofloxacin 67 ribavirin RBV 67 colorectal adenoma 67 antiangiogenic therapy 67 pegylated liposomal doxorubicin 67 thyroid carcinoma 67 invasive carcinomas 67 neoadjuvant therapy 67 antithymocyte globulin 67 salmeterol fluticasone 67 lymphadenectomy 67 node dissection 67 PSADT 67 androgen suppression 67 percutaneous drainage 67 gefitinib Iressa 67 Fulvestrant 67 metastatic bone 67 endoscopic resection 67 transarterial 67 serum cortisol 67 abacavir lamivudine 67 liposomal amphotericin B 67 Natalizumab 67 carboplatin paclitaxel 67 metastatic malignant 67 liposome formulation 67 hepatorenal syndrome 67 pancreatic adenocarcinoma 67 pT2 67 metastatic neuroendocrine tumors 67 FUSILEV enhances 67 thalidomide Thalomid 67 transrectal ultrasound guided 67 gastroduodenal 67 ultrasonographic 67 recurrent metastatic 67 FOLFOX4 67 Doxil ® 67 temozolomide TMZ 67 FOLFOX chemotherapy 67 tumor lysis syndrome 67 somatostatin analog 66 β blockers 66 colorectal cancer liver metastases 66 transurethral resection 66 tissue oxygenation 66 locoregional disease 66 TRUS 66 alfa 2a 66 pulmonary artery banding 66 estramustine 66 liposomal doxorubicin 66 neointimal hyperplasia 66 BCG refractory 66 etoposide 66 ALA PDT 66 fallopian tube cancers 66 patients undergoing CABG 66 conformal radiotherapy 66 recurrent glioblastoma multiforme 66 percutaneous biopsy 66 pelvic lymphadenectomy 66 myelosuppressive 66 parathyroid carcinoma 66 Gliadel Wafer 66 intraperitoneal chemotherapy 66 anthracycline taxane 66 Leucovorin 66 dose atorvastatin 66 drug eluting stent implantation 66 leiomyomas 66 parathyroidectomy 66 peritoneal carcinomatosis 66 graft occlusion 66 IOP lowering 66 clinicopathological features 66 carcinoids 66 metastatic gastric 66 metastatic malignant melanoma 66 deep venous thromboses 66 androgen ablation 66 intracranial hemorrhage ICH 66 idarubicin 66 T1c 66 Coronary Artery Bypass Graft 66 ablative therapy 66 renal tumors 66 gemcitabine Gemzar ® 66 CIN2 + 66 Intravitreal 66 intravenous cyclophosphamide 66 Patients Receiving 66 leukemia AML 66 certolizumab 66 mitoxantrone plus 66 radical nephrectomy 66 tirofiban 66 antiplatelet medications 66 4mg/kg 66 gemcitabine carboplatin 66 esophageal carcinoma 66 #Gy 66 LHRH agonists 66 Cystectomy 66 antithrombotic therapy 66 neutropenic sepsis 66 Neoadjuvant 66 bacillus Calmette Guerin 66 Elitek 66 cisplatin chemotherapy 66 Adjunctive 66 urodynamic 66 tumor histology 66 arteriography 66 atrioventricular block 66 cinacalcet 66 periprocedural 66 cyclophosphamide doxorubicin vincristine 66 transarterial chemoembolization 66 CTAP# Capsules 66 adenomatous 66 Triapine R 66 pyridostigmine 66 CYT# potent vascular disrupting 66 neoadjuvant treatment 66 Prognostic factors 66 cervical lymph nodes 66 obstructive CAD 66 nonmetastatic prostate cancer 66 melphalan prednisone 66 acute GvHD 66 BrachySil TM 66 ara C 66 allogeneic hematopoietic stem cell 66 pancreatectomy 66 endocrine therapies 66 antiretroviral naïve 66 nodal metastasis 66 interstitial brachytherapy 66 hepatocellular 65 skeletal metastases 65 thrombocytosis 65 prednisone prednisolone 65 colorectal carcinoma 65 Irinotecan 65 Intravenous immunoglobulin 65 metastatic pancreatic 65 Prognostic significance 65 trastuzumab Herceptin ® 65 autologous SCT 65 endometrial carcinoma 65 Nilotinib 65 GP IIb IIIa inhibitors 65 mycophenolate mofetil MMF 65 ® lenalidomide 65 % CI #.#-#.# [003] 65 oral clodronate 65 Xanafide 65 intravesical 65 5-FU/LV 65 spontaneous bacterial peritonitis 65 unfractionated heparin UFH 65 MGd 65 docetaxel Taxotere ® 65 venography 65 oral Hycamtin 65 LHRH receptor positive 65 morphometric vertebral fractures 65 Helicobacter pylori eradication 65 intrahepatic 65 benign prostatic hyperplasia enlarged 65 oral anticoagulant therapy 65 cTnI 65 intratumoral 65 colorectal adenocarcinoma 65 doxorubicin docetaxel 65 decompensated cirrhosis 65 Transurethral 65 Tumor Response 65 comparator arm 65 Orally administered 65 ER CHOP 65 Tacrolimus 65 transthoracic 65 LV ejection fraction 65 thrombotic complications 65 Thal Dex 65 epoetin alpha 65 tipranavir r 65 NAVISTAR R 65 SSc 65 mg/m2 dose 65 daily subcutaneous injections 65 AGILECT R 65 cystectomy 65 contralateral breast 65 Lenalidomide 65 Plasma concentrations 65 Panzem R NCD 65 busulfan 65 eptifibatide 65 urothelial cancer 65 ASCT 65 histologically proven 65 Percutaneous vertebroplasty 65 urothelial bladder cancer 65 surgically resected 65 Anti Bacterial Envelope 65 Secondary endpoints included 65 inotropic 65 immunomodulatory therapy 65 HIPEC 65 underwent surgical resection 65 biliary tract cancer 65 palifermin 65 sonographically guided 65 localized renal 65 symptomatic VTE 65 essential thrombocythemia ET 65 progression TTP 65 chemoresistant 65 TMP SMX 65 nephron sparing surgery 65 antiangiogenic agents 65 basal cell carcinoma BCC 65 potentially hepatotoxic 65 postoperative AF 65 hypervascular tumors 65 5 FU leucovorin 65 peritumoral 65 glucocorticoid induced 65 induce remission 65 Xelox 65 ovarian malignancy 65 urography 65 revascularization procedures 65 recurrent DVT 65 intravascular hemolysis 65 lumbar disk herniation 65 triiodothyronine 65 adjuvant therapies 65 intravesical chemotherapy 65 nonischemic 65 mitomycin C 65 Carotid endarterectomy 65 myeloablative 65 epithelial tumors 65 gastric adenocarcinoma 65 paclitaxel carboplatin 65 malignant neoplasms 65 5 Fluorouracil 65 intracoronary 65 thromboembolic complications 65 radical cystectomy 65 paclitaxel poliglumex 65 docetaxel Taxotere 65 HIV HCV coinfected 65 Gastrointestinal Stromal Tumors 65 bronchogenic carcinoma 65 malignant ascites 65 neo adjuvant 65 polycythemia vera essential thrombocythemia 65 hepatic arterial 65 isoenzyme 65 Pegylated Liposomal Doxorubicin 65 anti angiogenic agents 65 oral rivaroxaban 65 gemcitabine cisplatin 65 renal cysts 65 leiomyoma 65 spinal metastases 65 angiographically 65 scintigraphic 65 Erlotinib 65 dose cytarabine 65 hyperalgesia 65 cardiac repolarization 65 immunostaining 65 Intra arterial 65 Adjuvant chemotherapy 65 resectable 65 Preoperative 65 hyperplasia BPH 65 follicular thyroid cancer 65 doxorubicin cyclophosphamide 65 histologically confirmed 65 AST ALT 65 lymph node metastasis 65 bone scintigraphy 65 overlapping toxicities 65 hemorrhagic complications 65 FDG-PET/CT 65 vapreotide acetate 65 SPRYCEL ® 65 prostatic tissue 65 metastatic lymph nodes 65 zoledronate 65 superficial femoral 65 baseline LDH 65 Naive Patients 65 stage IIIb IV 65 nonalcoholic steatohepatitis NASH 65 androgen deprivation 65 cytotoxic therapy 65 inhibit platelet function 65 CHOP chemotherapy 65 papillary carcinoma 64 CIMZIA TM 64 TO AVOID PREGNANCY WHILE 64 Pemetrexed 64 thetreatment 64 conventional DMARDs 64 primary aldosteronism 64 HER2 expression 64 recurrent NSCLC 64 myocardial revascularization 64 fibrinolysis 64 tracheal intubation 64 Partial Response 64 activated partial thromboplastin 64 Immunohistochemical staining 64 noninvasive outpatient 64 prognostic variables 64 imexon 64 cerebral vasospasm 64 fibrinolytic therapy 64 piperacillin tazobactam 64 thoracoscopic lobectomy 64 extracapsular extension 64 corticosteroid therapy 64 ß blockers 64 Epirubicin 64 Fluorouracil 64 FOLFOX6 chemotherapy regimen 64 Peginterferon 64 platelet inhibitor 64 pulmonary resection 64 pretransplant 64 clinically meaningful reductions 64 mesalamine granules 64 Actinic Keratosis 64 hypofractionated 64 metastatic GIST 64 alfuzosin 64 mitomycin 64 epirubicin 64 invasive aspergillosis 64 hepatic tumors 64 cystoid macular edema 64 Chemoradiation 64 prostate cancer PCa 64 metaplasia 64 colon carcinoma 64 NATRECOR ® 64 intra arterial 64 extracranial 64 infusional 64 lactate dehydrogenase LDH 64 pain palliation 64 euthyroid 64 transvaginal sonography 64 lenalidomide Revlimid R 64 teriflunomide 64 hepatic resection 64 pegylated liposomal doxorubicin PLD 64 ductal adenocarcinoma 64 recurrent GBM 64 chronic thromboembolic pulmonary 64 Antibiotic prophylaxis 64 perioperative complications 64 mCi 64 percutaneous vertebroplasty 64 preoperative PSA 64 bladder carcinoma 64 drug zotarolimus 64 prostate cancer CaP 64 hyperparathyroidism 64 sorafenib Nexavar 64 PegIFN RBV 64 advanced adenomas 64 bleomycin 64 prostate cancer CRPC 64 lymphocyte count 64 primidone 64 pharmacodynamic parameters 64 Atypical Hemolytic Uremic Syndrome 64 nodal dissection 64 intratympanic 64 calcaneal fractures 64 Abciximab 64 lymphocytosis 64 functional mitral regurgitation 64 tuberous sclerosis TS 64 prospective multicenter study 64 Retreatment 64 interleukin IL -6 64 Pegylated interferon 64 paragangliomas 64 biliary obstruction 64 androgen blockade 64 HoLEP 64 lymphoid malignancies 64 antiangiogenic agent 64 prognostic indicator 64 antitumor effect 64 GORE TAG Device 64 Oxaliplatin 64 recurrent prostate cancer 64 #beta estradiol 64 femoral neck fracture 64 gemtuzumab ozogamicin 64 tamoxifen Nolvadex ® 64 pulmonary metastases 64 sitaxsentan 64 secondary hyperparathyroidism 64 recurrent malignant glioma 64 histological subtype 64 cytoreductive nephrectomy 64 perioperative morbidity 64 oblimersen 64 evaluating tivozanib 64 HeFH 64 fluticasone salmeterol 64 interferon alfa 2a 64 Platinol ® 64 chemoradiation 64 symptomatic intracranial 64 Endometrial 64 aspirin clopidogrel 64 intermittent hemodialysis 64 fosbretabulin 64 taxane resistant 64 clevidipine 64 preoperative diagnosis 64 steroid refractory 64 clodronate 64 oncologic outcomes 64 caspofungin 64 hyperphenylalaninemia HPA due 64 prespecified secondary 64 neutropenia dehydration dyspnea 64 pulmonary infiltrates 64 tenecteplase 64 PEGylated interferon 64 Cardiotoxicity 64 refractory AML 64 myelodysplastic myeloproliferative diseases 64 Fontan procedure 64 isoproterenol 64 trastuzumab Herceptin R 64 cranial irradiation 64 duplex ultrasonography 64 perfusion abnormalities 64 acetazolamide 64 node metastases 64 vaginal hysterectomy 64 treat benign prostatic 64 breast carcinoma 64 allogeneic HSCT 64 histologic findings 64 mutated K ras 64 needle aspiration 64 tamsulosin 64 galiximab 64 nadolol 64 cardiac perfusion 64 imatinib therapy 64 everolimus eluting stents 64 BENICAR HCT 64 intraventricular 64 pegylated IFN 64 paclitaxel eluting stents 64 dose melphalan 64 situ CIS 64 TNF antagonist 64 fibrin deposition 64 saline placebo 64 Free Survival PFS 64 ALND 64 moderate renal impairment 64 verteporfin 64 fluoropyrimidine 64 allogeneic hematopoietic cell 64 myocardial necrosis 64 labetalol 64 IIIa inhibitor 64 irinotecan doxorubicin oxaliplatin paclitaxel 64 NSABP B 64 plasma uric acid 64 thromboembolic disease 64 ibritumomab tiuxetan 64 sarcomatoid 64 Gemcitabine 64 operable breast cancer 64 Mitoxantrone 64 DOXIL 64 NPM1 mutation 64 T2DM 64 mycophenolate mofetil 64 percutaneous ablation 64 symptomatic paroxysmal AF 64 TMC# r 64 somatostatin analogues 64 dosage regimens 64 smoldering multiple myeloma 64 #mg/m# [001] 64 tolterodine ER 64 overt nephropathy 64 hyperinsulinemic euglycemic clamp 64 Vidaza ® 64 goserelin 64 paclitaxel Taxol 64 K ras mutations 63 venous thromboembolic disease 63 patientswith 63 Aptivus ® 63 platelet dysfunction 63 antiandrogen 63 kidney urologic 63 KRAS mutations occur 63 hyperacute 63 advanced hepatocellular carcinoma 63 echocardiographic parameters 63 microsatellite instability 63 transesophageal echocardiography 63 recombinant tissue plasminogen 63 docetaxel chemotherapy 63 Anthracycline 63 gastric carcinoma 63 hormone receptor negative 63 abacavir Ziagen 63 SLNB 63 8mg/kg 63 antibiotic prophylaxis 63 inhaled iloprost 63 azacytidine 63 achieved CCyR 63 folinic acid 63 Hormone Refractory Prostate Cancer 63 pg ml 63 ATACAND 63 Fine needle aspiration 63 bovine thrombin 63 myopathy rhabdomyolysis 63 deferoxamine 63 intracavitary 63 ischemia induced 63 diagnosing coronary artery 63 EDEMA3 trial 63 chronic GVHD 63 benign neoplasms 63 cGy 63 genotypic resistance 63 postmenopausal osteoporotic women 63 bronchoalveolar lavage BAL 63 Etoposide 63 intradermal injections 63 Cardiopulmonary bypass 63 treated nonsurgically 63 dalteparin 63 ARB telmisartan 63 pharmacodynamic PD 63 topically administered 63 distant metastases 63 ovarian carcinoma 63 Postoperative 63 renal artery stenting 63 Squamous 63 primary hyperparathyroidism 63 voriconazole 63 lipid lowering agents 63 infused intravenously 63 lung resection 63 GISTs 63 hamartomas 63 conventional angiography 63 FluCAM arm 63 directed thrombolysis 63 adjunctive therapies 63 Hypotension 63 hemodynamic variables 63 pharmacokinetic parameters 63 pioglitazone HCl 63 para aortic 63 Fludarabine 63 Adjuvant therapy 63 anemia thrombocytopenia 63 trabeculectomy 63 P = .# 63 neovascularisation 63 postoperative mortality 63 T1a 63 thromboembolic events 63 taxane chemotherapy 63 chemotherapy cisplatin 63 metachronous 63 precursor lesions 63 EGFR mutation positive 63 otamixaban 63 aminotransferases 63 CsA 63 myocardial viability 63 invasive candidiasis 63 Gemzar gemcitabine 63 serum TSH 63 glycoprotein IIb IIIa inhibitors 63 chronic hemodialysis 63 radiotherapeutic 63 Peg IFN 63 percutaneous injection 63 recurrent glioblastoma 63 FOLFIRI alone 63 CLL SLL 63 IV bisphosphonates 63 glycoprotein IIb IIIa inhibitor 63 IV bolus 63 ischemic mitral regurgitation 63 liver histology 63 anthracycline chemotherapy 63 GnRH agonists 63 unstable angina pectoris 63 adalimumab Humira 63 benign prostatic hypertrophy BPH 63 dacarbazine 63 prostatic adenocarcinoma 63 vertebrobasilar 63 zonisamide SR 63 postintervention 63 intestinal metaplasia 63 RRM1 63 PCa 63 mitoxantrone 63 resected pancreatic cancer 63 variceal hemorrhage 63 Telintra 63 tibial plateau fractures 63 polycythemia vera PV 63 histopathologic examination 63 paracentesis 63 p = NS 63 p# biomarker 63 Fludara ® 63 intra articular injection 63 invasive coronary angiography 63 lesional 63 non squamous histology 63 immunomodulatory agents 63 hMG 63 cholelithiasis 63 metastatic bladder 63 Soft Tissue Sarcoma 63 subtrochanteric 63 sirolimus eluting stents 63 GnRH agonist 63 Temodar ® 63 rFSH 63 Moxifloxacin 63 platelet reactivity 63 fluticasone propionate FP 63 nonmetastatic 63 refractory colorectal cancer 63 Patients Treated With 63 Renal Cell Carcinoma RCC 63 lymphomas leukemias 63 extrapleural pneumonectomy 63 iPTH 63 methotrexate monotherapy 63 Kinoid 63 serum calcium levels 63 Castration Resistant Prostate Cancer 63 hepatic fibrosis 63 Central Venous Catheter 63 grade squamous intraepithelial 63 PREZISTA ritonavir 63 corifollitropin alfa 63 computed tomography angiography 63 systemic hypotension 63 EBUS TBNA 63 vincristine doxorubicin 63 PASI scores 63 vinorelbine tartrate 63 Patency 63 MitraClip device 63 octreotide LAR 63 levodopa induced 63 pseudoaneurysm 63 receiving XGEVA 63 CC genotype 63 hepatic insufficiency 63 CK MB 63 rebleeding 63 intima media thickness 63 micrometastasis 63 catheter occlusion 63 flutamide 63 nodal metastases 63 Bosentan 63 angiography CTA 63 intrathoracic 63 interferon alfa 2b 63 Interferon Beta 63 percutaneous nephrolithotomy 63 TURP 63 KRAS status 63 PegIFN 63 dose cyclophosphamide 63 hematologic toxicity 63 neutrophil counts 63 proximal DVT 63 administered subcutaneously 63 chromosomal mutations 63 cisplatin vinorelbine 63 radiation chemoradiation 63 meniscectomy 63 endothelial activation 63 surgical resection cavity 63 hemoglobin Hb 63 inotropic therapy 63 esophageal gastric 63 Myelodysplastic Syndrome MDS 63 microbiological eradication 63 ritonavir boosted protease inhibitor 63 pleural fluid 63 Acute Ischemic Stroke 63 interleukin IL -# 63 sclerosing 63 vinca alkaloid 63 lymphoproliferative disorders 63 serum aminotransferase levels 63 GPIIb IIIa inhibitors 63 plasma creatinine 63 mycophenolic acid 63 troponins 63 tumors GIST 63 nephrotoxic 63 mucosal inflammation 63 pegylated interferon alfa 63 serum phosphate 63 dasatinib Sprycel ® 63 thrombolytics 63 metastatic RCC 63 corticosteroid dose 63 RhuDex TM 63 Cytarabine 63 stratifying patients 63 paricalcitol 63 hip BMD 63 Bisphosphonate 63 colorectal metastases 63 adnexal masses 63 TPV r 63 perioperative mortality 63 Secondary endpoints include 63 rhITF 63 Newly Diagnosed Multiple Myeloma 63 resected 63 ErbB2 positive 63 peripheral arterial occlusive disease 63 prognostic significance 63 Diabetic Foot Ulcer 63 QT QTc 63 multivariate Cox 63 dasatinib Sprycel 63 seminal vesicle invasion 63 alkylating agent 63 subcutaneous enoxaparin 63 Nebulized 63 malignant pleural mesothelioma MPM 63 CRp 63 indinavir 63 bypass grafting 63 adjuvant therapy 63 AZT zidovudine Retrovir 63 occlusive disease 63 cytopenias 63 dimensional echocardiography 63 ropivacaine 63 Ultrasound guided 63 stem cell engraftment 63 inhibitor RG# 63 radical retropubic prostatectomy 63 allograft rejection 63 oral antidiabetic medication 63 humanised monoclonal antibody 63 glycosylated hemoglobin HbA1c 63 systemic amyloidosis 63 microvessel density 63 undetectable HBV DNA 63 prostate TURP 63 variceal bleeding 63 Percutaneous Transluminal Coronary Angioplasty 63 Vicinium TM 63 reinfarction 63 undergone radical prostatectomy 63 lactate dehydrogenase 63 lenalidomide Revlimid 63 Cypher Stent 63 capecitabine Xeloda 63 Neulasta ® 63 IRX 2 63 renal biopsy 63 mesalazine 63 LHRH analogues 63 EGFRIs 63 stage IIIB 63 posttreatment 63 p = #.# [003] 63 squamous cell carcinoma SCC 62 cardiotoxic 62 immune modulating 62 unresectable HCC 62 octreotide 62 posttransplant 62 APTIVUS r 62 QTc prolongation 62 peritoneal cancer 62 Bezielle 62 endoscopic retrograde 62 osteogenic 62 RENAL 62 lymph node involvement 62 NSAID induced 62 creatine kinase MB 62 renal artery stenosis 62 axillary dissection 62 Interferon beta 62 fibrinolytic 62 Interferon alfa 62 tumor xenograft models 62 pCR 62 coronary stenosis 62 pulmonary artery hypertension 62 lung fibrosis 62 FVIIa 62 alpha1 antitrypsin deficiency 62 radiosensitivity 62 -#.# ± [002] 62 neutropaenia 62 nephrotoxicity 62 Danazol 62 refractory NSCLC 62 Papillary 62 antimicrobial prophylaxis 62 mL/min/#.# m 2 62 ribavirin therapy 62 Bacillus Calmette Guerin BCG 62 Protelos R 62 curative resection 62 thyrotoxicosis 62 Hyperlipidemia 62 hematological parameters 62 denileukin diftitox 62 parathyroid 62 NeoLipid R 62 corticosteroid dexamethasone 62 pheochromocytoma 62 metaglidasen 62 peritumoral brain edema 62 autologous transplantation 62 Adjuvant Treatment 62 achieved ACR# 62 GMX# 62 INTEGRILIN R 62 #.#ng/ml 62 Liver transplantation 62 severe neutropenia 62 VATS lobectomy 62 FASLODEX 62 FFR guided 62 intradermal injection 62 ibandronate 62 Coronary artery bypass graft 62 antimitotic 62 osteoid 62 pathologic diagnosis 62 dosimetric 62 secondary efficacy endpoint 62 lymphadenopathy 62 tricuspid regurgitation 62 osteoid osteoma 62 Tasigna prolongs 62 HBeAg negative 62 underwent radical cystectomy 62 induce orthostatic hypotension 62 μg liter 62 candidemia 62 tumoral 62 myeloid metaplasia 62 antiarrhythmic drug 62 novel VDA molecule 62 Mg Usa 62 myeloproliferative diseases 62 MYLOTARG 62 AVAPRO 62 refractory ovarian cancer